Jefferies analyst Eun Yang maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) yesterday and set a price target of $78.00. The company's shares closed last Thursday at $58.77, close to its 52-week low of $50.96. According to TipRanks.com, Yang is a 4-star analyst with an average return of 3.2% and a 46.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Aerovate Therapeutics, and Taysha Gene Therapies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $89.00 average price target, a 41.0% upside from current levels.
https://www.tipranks.com/news/blurbs/jefferies-thinks-blueprint-medicines-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Blueprint Medicines Charts.